(19)
(11) EP 1 895 984 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.05.2010 Bulletin 2010/19

(45) Mention of the grant of the patent:
03.03.2010 Bulletin 2010/09

(21) Application number: 06772091.2

(22) Date of filing: 05.06.2006
(51) International Patent Classification (IPC): 
A61K 9/14(2006.01)
 A61K 31/506(2006.01)
(86) International application number:
PCT/US2006/021657
(87) International publication number:
WO 2006/133046 (14.12.2006 Gazette 2006/50)

(54)

NANOPARTICULATE IMATINIB MESYLATE FORMULATIONS

NANOTEILCHENFÖRMIGE IMATINIB-MESYLAT-FORMULIERUNGEN

FORMULATIONS D'IMATINIB MESYLATE NANOPARTICULAIRES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 03.06.2005 US 687146 P

(43) Date of publication of application:
12.03.2008 Bulletin 2008/11

(73) Proprietor: Elan Pharma International Limited
County Westmeath (IE)

(72) Inventors:
  • JENKINS, Scott
    Downingtown, PA 19335 (US)
  • LIVERSIDGE, Gary, G.
    Westchester, PA 19380 (US)

(74) Representative: Pohlman, Sandra M. 
df-mp Fünf Höfe Theatinerstrasse 16
80333 München
80333 München (DE)


(56) References cited: : 
WO-A-2006/054314
US-A1- 2005 042 177
 WO-A-2006/110811
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).